Loading…
Pathways Forward in Cardiovascular Disease Prevention One and a Half Years After Publication of the 2013 ACC/AHA Cardiovascular Disease Prevention Guidelines
Abstract The 2013 American College of Cardiology/American Heart Association cardiovascular disease prevention guidelines represent an important step forward in the risk assessment and management of atherosclerotic cardiovascular disease in clinical practice. Differentiated risk prediction equations...
Saved in:
| Published in: | Mayo Clinic proceedings 2015-09, Vol.90 (9), p.1262-1271 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c668t-940754e290d25b06f76c472786cb19b12b272bb68c6af1a4ef6ce4840ca613223 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c668t-940754e290d25b06f76c472786cb19b12b272bb68c6af1a4ef6ce4840ca613223 |
| container_end_page | 1271 |
| container_issue | 9 |
| container_start_page | 1262 |
| container_title | Mayo Clinic proceedings |
| container_volume | 90 |
| creator | Cainzos-Achirica, Miguel, MD Desai, Chintan S., MD, MSc Wang, Libin, MD Blaha, Michael J., MD, MPH Lopez-Jimenez, Francisco, MD, MSc Kopecky, Stephen L., MD Blumenthal, Roger S., MD Martin, Seth S., MD, MHS |
| description | Abstract The 2013 American College of Cardiology/American Heart Association cardiovascular disease prevention guidelines represent an important step forward in the risk assessment and management of atherosclerotic cardiovascular disease in clinical practice. Differentiated risk prediction equations for women and black individuals were developed, and convenient 10-year and lifetime risk assessment tools were provided, facilitating their implementation. Lifestyle modification was portrayed as the foundation of preventive therapy. In addition, based on high-quality evidence from randomized controlled trials, statins were prioritized as the first lipid-lowering pharmacologic treatment, and a shared decision-making model between the physician and the patient was emphasized as a key feature of personalized care. After publication of the guidelines, however, important limitations were also identified. This resulted in a constructive scientific debate yielding valuable insights into potential opportunities to refine recommendations, fill gaps in guidance, and better harmonize recommendations within and outside the United States. The latter point deserves emphasis because when guidelines are in disagreement, this may result in nonaction on the part of professional caregivers or nonadherence by patients. In this review, we discuss the key scientific literature relevant to the guidelines published in the year and a half after their release. We aim to provide cohesive, evidence-based views that may offer pathways forward in cardiovascular disease prevention toward greater consensus and benefit the practice of clinical medicine. |
| doi_str_mv | 10.1016/j.mayocp.2015.05.018 |
| format | article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1711537695</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A430717183</galeid><els_id>S0025619615005121</els_id><sourcerecordid>A430717183</sourcerecordid><originalsourceid>FETCH-LOGICAL-c668t-940754e290d25b06f76c472786cb19b12b272bb68c6af1a4ef6ce4840ca613223</originalsourceid><addsrcrecordid>eNqNksGO0zAQhiMEYkvhDRCyhIQ40K7tJE5yQYoCu0VaaSsBB06W40xaFzfuepKu-jC8K852gaUXkEceyfr-8Xj8R9FLRueMMnG-mW_VwendnFOWzmkIlj-KJqxI-CxNE_E4mlDK05lghTiLniFuKKVZUSRPozMuuCgYzSfRj6Xq17fqgOTC-VvlG2I6UoVs3F6hHqzy5INBUAhk6WEPXW9cR647IKpriCILZVvyDZRHUrY9eLIcamu0usNcS_o1kNBhTMqqOi8X5X8UvxxMA9Z0gM-jJ62yCC_u8zT6evHxS7WYXV1ffqrKq5kWIu9nRUKzNAFe0IanNRVtJnSS8SwXumZFzXjNM17XItdCtUwl0AoNSZ5QrQSLOY-n0dtj3Z13NwNgL7cGNVirOnADSpYxlsaZKNKAvj5BN27wXejujgrTLlIWqPmRWikL0nSt673SYTWwNdp10JpwXiYxzYIqj4PgzQPBGpTt1-jsMA4E_wbfPQDrAcc5hQ3Nat3jSg14gidHXHuH6KGVO2-2yh8ko3L0kdzIo4_k6CNJQwTdNHp1_8qh3kLzW_TLOAF4fwQgfMvegJeoDXQaGuNB97Jx5l83nBbQ4cuDcex3OAD-GapELqn8PHp5tDJLKU0ZZ_FPd1DtbA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1711619951</pqid></control><display><type>article</type><title>Pathways Forward in Cardiovascular Disease Prevention One and a Half Years After Publication of the 2013 ACC/AHA Cardiovascular Disease Prevention Guidelines</title><source>ScienceDirect - Connect here FIRST to enable access</source><creator>Cainzos-Achirica, Miguel, MD ; Desai, Chintan S., MD, MSc ; Wang, Libin, MD ; Blaha, Michael J., MD, MPH ; Lopez-Jimenez, Francisco, MD, MSc ; Kopecky, Stephen L., MD ; Blumenthal, Roger S., MD ; Martin, Seth S., MD, MHS</creator><creatorcontrib>Cainzos-Achirica, Miguel, MD ; Desai, Chintan S., MD, MSc ; Wang, Libin, MD ; Blaha, Michael J., MD, MPH ; Lopez-Jimenez, Francisco, MD, MSc ; Kopecky, Stephen L., MD ; Blumenthal, Roger S., MD ; Martin, Seth S., MD, MHS</creatorcontrib><description>Abstract The 2013 American College of Cardiology/American Heart Association cardiovascular disease prevention guidelines represent an important step forward in the risk assessment and management of atherosclerotic cardiovascular disease in clinical practice. Differentiated risk prediction equations for women and black individuals were developed, and convenient 10-year and lifetime risk assessment tools were provided, facilitating their implementation. Lifestyle modification was portrayed as the foundation of preventive therapy. In addition, based on high-quality evidence from randomized controlled trials, statins were prioritized as the first lipid-lowering pharmacologic treatment, and a shared decision-making model between the physician and the patient was emphasized as a key feature of personalized care. After publication of the guidelines, however, important limitations were also identified. This resulted in a constructive scientific debate yielding valuable insights into potential opportunities to refine recommendations, fill gaps in guidance, and better harmonize recommendations within and outside the United States. The latter point deserves emphasis because when guidelines are in disagreement, this may result in nonaction on the part of professional caregivers or nonadherence by patients. In this review, we discuss the key scientific literature relevant to the guidelines published in the year and a half after their release. We aim to provide cohesive, evidence-based views that may offer pathways forward in cardiovascular disease prevention toward greater consensus and benefit the practice of clinical medicine.</description><identifier>ISSN: 0025-6196</identifier><identifier>EISSN: 1942-5546</identifier><identifier>DOI: 10.1016/j.mayocp.2015.05.018</identifier><identifier>PMID: 26269108</identifier><identifier>CODEN: MACPAJ</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>American Heart Association ; Analysis ; Atherosclerosis - epidemiology ; Atherosclerosis - prevention & control ; Cardiovascular diseases ; Cardiovascular Diseases - epidemiology ; Cardiovascular Diseases - prevention & control ; Evidence-Based Medicine ; Female ; Global Health ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Internal Medicine ; Male ; Practice guidelines (Medicine) ; Practice Guidelines as Topic ; Prevention ; Preventive medicine ; Primary Prevention - organization & administration ; Risk Reduction Behavior ; Societies, Medical ; United States - epidemiology</subject><ispartof>Mayo Clinic proceedings, 2015-09, Vol.90 (9), p.1262-1271</ispartof><rights>Mayo Foundation for Medical Education and Research</rights><rights>2015 Mayo Foundation for Medical Education and Research</rights><rights>Copyright © 2015 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.</rights><rights>COPYRIGHT 2015 Frontline Medical Communications Inc.</rights><rights>Copyright Mayo Foundation for Medical Education and Research Sep 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c668t-940754e290d25b06f76c472786cb19b12b272bb68c6af1a4ef6ce4840ca613223</citedby><cites>FETCH-LOGICAL-c668t-940754e290d25b06f76c472786cb19b12b272bb68c6af1a4ef6ce4840ca613223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0025619615005121$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,786,790,3568,27957,27958,45815</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26269108$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cainzos-Achirica, Miguel, MD</creatorcontrib><creatorcontrib>Desai, Chintan S., MD, MSc</creatorcontrib><creatorcontrib>Wang, Libin, MD</creatorcontrib><creatorcontrib>Blaha, Michael J., MD, MPH</creatorcontrib><creatorcontrib>Lopez-Jimenez, Francisco, MD, MSc</creatorcontrib><creatorcontrib>Kopecky, Stephen L., MD</creatorcontrib><creatorcontrib>Blumenthal, Roger S., MD</creatorcontrib><creatorcontrib>Martin, Seth S., MD, MHS</creatorcontrib><title>Pathways Forward in Cardiovascular Disease Prevention One and a Half Years After Publication of the 2013 ACC/AHA Cardiovascular Disease Prevention Guidelines</title><title>Mayo Clinic proceedings</title><addtitle>Mayo Clin Proc</addtitle><description>Abstract The 2013 American College of Cardiology/American Heart Association cardiovascular disease prevention guidelines represent an important step forward in the risk assessment and management of atherosclerotic cardiovascular disease in clinical practice. Differentiated risk prediction equations for women and black individuals were developed, and convenient 10-year and lifetime risk assessment tools were provided, facilitating their implementation. Lifestyle modification was portrayed as the foundation of preventive therapy. In addition, based on high-quality evidence from randomized controlled trials, statins were prioritized as the first lipid-lowering pharmacologic treatment, and a shared decision-making model between the physician and the patient was emphasized as a key feature of personalized care. After publication of the guidelines, however, important limitations were also identified. This resulted in a constructive scientific debate yielding valuable insights into potential opportunities to refine recommendations, fill gaps in guidance, and better harmonize recommendations within and outside the United States. The latter point deserves emphasis because when guidelines are in disagreement, this may result in nonaction on the part of professional caregivers or nonadherence by patients. In this review, we discuss the key scientific literature relevant to the guidelines published in the year and a half after their release. We aim to provide cohesive, evidence-based views that may offer pathways forward in cardiovascular disease prevention toward greater consensus and benefit the practice of clinical medicine.</description><subject>American Heart Association</subject><subject>Analysis</subject><subject>Atherosclerosis - epidemiology</subject><subject>Atherosclerosis - prevention & control</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Evidence-Based Medicine</subject><subject>Female</subject><subject>Global Health</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Practice guidelines (Medicine)</subject><subject>Practice Guidelines as Topic</subject><subject>Prevention</subject><subject>Preventive medicine</subject><subject>Primary Prevention - organization & administration</subject><subject>Risk Reduction Behavior</subject><subject>Societies, Medical</subject><subject>United States - epidemiology</subject><issn>0025-6196</issn><issn>1942-5546</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNqNksGO0zAQhiMEYkvhDRCyhIQ40K7tJE5yQYoCu0VaaSsBB06W40xaFzfuepKu-jC8K852gaUXkEceyfr-8Xj8R9FLRueMMnG-mW_VwendnFOWzmkIlj-KJqxI-CxNE_E4mlDK05lghTiLniFuKKVZUSRPozMuuCgYzSfRj6Xq17fqgOTC-VvlG2I6UoVs3F6hHqzy5INBUAhk6WEPXW9cR647IKpriCILZVvyDZRHUrY9eLIcamu0usNcS_o1kNBhTMqqOi8X5X8UvxxMA9Z0gM-jJ62yCC_u8zT6evHxS7WYXV1ffqrKq5kWIu9nRUKzNAFe0IanNRVtJnSS8SwXumZFzXjNM17XItdCtUwl0AoNSZ5QrQSLOY-n0dtj3Z13NwNgL7cGNVirOnADSpYxlsaZKNKAvj5BN27wXejujgrTLlIWqPmRWikL0nSt673SYTWwNdp10JpwXiYxzYIqj4PgzQPBGpTt1-jsMA4E_wbfPQDrAcc5hQ3Nat3jSg14gidHXHuH6KGVO2-2yh8ko3L0kdzIo4_k6CNJQwTdNHp1_8qh3kLzW_TLOAF4fwQgfMvegJeoDXQaGuNB97Jx5l83nBbQ4cuDcex3OAD-GapELqn8PHp5tDJLKU0ZZ_FPd1DtbA</recordid><startdate>20150901</startdate><enddate>20150901</enddate><creator>Cainzos-Achirica, Miguel, MD</creator><creator>Desai, Chintan S., MD, MSc</creator><creator>Wang, Libin, MD</creator><creator>Blaha, Michael J., MD, MPH</creator><creator>Lopez-Jimenez, Francisco, MD, MSc</creator><creator>Kopecky, Stephen L., MD</creator><creator>Blumenthal, Roger S., MD</creator><creator>Martin, Seth S., MD, MHS</creator><general>Elsevier Inc</general><general>Frontline Medical Communications Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4U-</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20150901</creationdate><title>Pathways Forward in Cardiovascular Disease Prevention One and a Half Years After Publication of the 2013 ACC/AHA Cardiovascular Disease Prevention Guidelines</title><author>Cainzos-Achirica, Miguel, MD ; Desai, Chintan S., MD, MSc ; Wang, Libin, MD ; Blaha, Michael J., MD, MPH ; Lopez-Jimenez, Francisco, MD, MSc ; Kopecky, Stephen L., MD ; Blumenthal, Roger S., MD ; Martin, Seth S., MD, MHS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c668t-940754e290d25b06f76c472786cb19b12b272bb68c6af1a4ef6ce4840ca613223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>American Heart Association</topic><topic>Analysis</topic><topic>Atherosclerosis - epidemiology</topic><topic>Atherosclerosis - prevention & control</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Evidence-Based Medicine</topic><topic>Female</topic><topic>Global Health</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Practice guidelines (Medicine)</topic><topic>Practice Guidelines as Topic</topic><topic>Prevention</topic><topic>Preventive medicine</topic><topic>Primary Prevention - organization & administration</topic><topic>Risk Reduction Behavior</topic><topic>Societies, Medical</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cainzos-Achirica, Miguel, MD</creatorcontrib><creatorcontrib>Desai, Chintan S., MD, MSc</creatorcontrib><creatorcontrib>Wang, Libin, MD</creatorcontrib><creatorcontrib>Blaha, Michael J., MD, MPH</creatorcontrib><creatorcontrib>Lopez-Jimenez, Francisco, MD, MSc</creatorcontrib><creatorcontrib>Kopecky, Stephen L., MD</creatorcontrib><creatorcontrib>Blumenthal, Roger S., MD</creatorcontrib><creatorcontrib>Martin, Seth S., MD, MHS</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>University Readers</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>ProQuest Databases</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Science Journals</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Mayo Clinic proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cainzos-Achirica, Miguel, MD</au><au>Desai, Chintan S., MD, MSc</au><au>Wang, Libin, MD</au><au>Blaha, Michael J., MD, MPH</au><au>Lopez-Jimenez, Francisco, MD, MSc</au><au>Kopecky, Stephen L., MD</au><au>Blumenthal, Roger S., MD</au><au>Martin, Seth S., MD, MHS</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pathways Forward in Cardiovascular Disease Prevention One and a Half Years After Publication of the 2013 ACC/AHA Cardiovascular Disease Prevention Guidelines</atitle><jtitle>Mayo Clinic proceedings</jtitle><addtitle>Mayo Clin Proc</addtitle><date>2015-09-01</date><risdate>2015</risdate><volume>90</volume><issue>9</issue><spage>1262</spage><epage>1271</epage><pages>1262-1271</pages><issn>0025-6196</issn><eissn>1942-5546</eissn><coden>MACPAJ</coden><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-3</notes><notes>content type line 23</notes><notes>ObjectType-Review-1</notes><abstract>Abstract The 2013 American College of Cardiology/American Heart Association cardiovascular disease prevention guidelines represent an important step forward in the risk assessment and management of atherosclerotic cardiovascular disease in clinical practice. Differentiated risk prediction equations for women and black individuals were developed, and convenient 10-year and lifetime risk assessment tools were provided, facilitating their implementation. Lifestyle modification was portrayed as the foundation of preventive therapy. In addition, based on high-quality evidence from randomized controlled trials, statins were prioritized as the first lipid-lowering pharmacologic treatment, and a shared decision-making model between the physician and the patient was emphasized as a key feature of personalized care. After publication of the guidelines, however, important limitations were also identified. This resulted in a constructive scientific debate yielding valuable insights into potential opportunities to refine recommendations, fill gaps in guidance, and better harmonize recommendations within and outside the United States. The latter point deserves emphasis because when guidelines are in disagreement, this may result in nonaction on the part of professional caregivers or nonadherence by patients. In this review, we discuss the key scientific literature relevant to the guidelines published in the year and a half after their release. We aim to provide cohesive, evidence-based views that may offer pathways forward in cardiovascular disease prevention toward greater consensus and benefit the practice of clinical medicine.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>26269108</pmid><doi>10.1016/j.mayocp.2015.05.018</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-6196 |
| ispartof | Mayo Clinic proceedings, 2015-09, Vol.90 (9), p.1262-1271 |
| issn | 0025-6196 1942-5546 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1711537695 |
| source | ScienceDirect - Connect here FIRST to enable access |
| subjects | American Heart Association Analysis Atherosclerosis - epidemiology Atherosclerosis - prevention & control Cardiovascular diseases Cardiovascular Diseases - epidemiology Cardiovascular Diseases - prevention & control Evidence-Based Medicine Female Global Health Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Internal Medicine Male Practice guidelines (Medicine) Practice Guidelines as Topic Prevention Preventive medicine Primary Prevention - organization & administration Risk Reduction Behavior Societies, Medical United States - epidemiology |
| title | Pathways Forward in Cardiovascular Disease Prevention One and a Half Years After Publication of the 2013 ACC/AHA Cardiovascular Disease Prevention Guidelines |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T20%3A22%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pathways%20Forward%20in%20Cardiovascular%20Disease%20Prevention%20One%20and%20a%20Half%20Years%20After%20Publication%20of%20the%202013%20ACC/AHA%20Cardiovascular%20Disease%20Prevention%20Guidelines&rft.jtitle=Mayo%20Clinic%20proceedings&rft.au=Cainzos-Achirica,%20Miguel,%20MD&rft.date=2015-09-01&rft.volume=90&rft.issue=9&rft.spage=1262&rft.epage=1271&rft.pages=1262-1271&rft.issn=0025-6196&rft.eissn=1942-5546&rft.coden=MACPAJ&rft_id=info:doi/10.1016/j.mayocp.2015.05.018&rft_dat=%3Cgale_proqu%3EA430717183%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c668t-940754e290d25b06f76c472786cb19b12b272bb68c6af1a4ef6ce4840ca613223%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1711619951&rft_id=info:pmid/26269108&rft_galeid=A430717183&rfr_iscdi=true |